BioCryst Finds Its European Sherpa for HAE Drug

BioCryst licenses navenibart to Neopharmed Gentili for European commercialization, unlocking $70M upfront and up to $275M in milestones

9 Jun 2026

On May 4, BioCryst Pharmaceuticals handed European commercialization rights for navenibart to Neopharmed Gentili, a deal that pays $70 million upfront, up to $275 million in milestones, and royalties running between 18 and 30% of European net sales. The drug targets hereditary angioedema, a rare genetic disorder that causes sudden, severe swelling in the face, throat, abdomen, and limbs. Without timely treatment, an attack can be fatal.

What sets navenibart apart is its dosing schedule: once every three to six months. No approved prophylactic currently comes close to that interval, making it a meaningful departure from the frequent injection regimens patients manage today.

The partnership is not a cold introduction. Neopharmed Gentili already runs the European commercial infrastructure it built around BioCryst's Orladeyo therapy after acquiring those rights in 2025. Dropping navenibart into that same operation means faster market reach without BioCryst rebuilding a regional footprint from scratch. BioCryst keeps full US commercial control, capturing European upside through milestones and royalties while sidestepping the fixed costs of a dedicated regional operation.

BioCryst acquired navenibart through its $700 million purchase of Astria Therapeutics in January 2026. Phase 1b/2 data showed attack reductions exceeding 90 percent in some patient cohorts. The drug is now in Phase 3, with a US regulatory filing targeted for late 2027.

Structuring deals this way has become standard practice in rare disease commercialization, where the economics of small patient populations reward asset-sharing over parallel builds. For BioCryst, the arrangement funds Phase 3 completion and a US launch without burning through capital on European operations. For patients across the continent currently managing HAE through demanding, frequent injections, a drug requiring just two to four doses per year is now advancing through late-stage development.